Assessment of immunomodulation and regulation of cell cycle in epithelium and stroma after Cidofovir injection in patients with recurrent respiratory papillomatosis—Pilot study

Abstract

Recurrent respiratory papillomatosis is strictly connected with human papillomavirus (HPV) infection of the epithelium of the upper respiratory tract. The main treatment of lesions located in the larynx or lower pharynx includes microsurgical excision by using a CO2 laser. To decrease the amount of surgical procedures gain in importance combined therapy with antiviral agents. The aim of this study was to investigate the effect of the intralesional application of Cidofovir on the tissue of laryngeal papillomas. We have shown that simultaneous microsurgery with adjuvant therapy of Cidofovir reduces chronic inflammation (by measuring the expression of CD4 and CD8 in tissue samples), cell proliferation, and regulates the cell cycle of HPV‐infected cells by reducing the expression of p53 and p63 proteins. In addition, this strategy reduces the multiple surgical procedures and regrowth of the pathology.

Cutaneous Applications of the Antiviral Drug Cidofovir: A Review

“…Used as an adjuvant to surgery, IL cidofovir was shown to reduce the number of surgical interventions and achieve the curing of recurrent respiratory papillomatosis [62]. This study quantified the presence of these lymphocytes in conjunction with cell cycle regulators (p16, p53, p63, Ki-67 proteins) in 24 patients with histopathologically confirmed papillomas caused by human papillomavirus (HPV) infection, both before and after treatment with IL cidofovir [62]. The drug influence on the tissue was demonstrated via decreased inflammation (epithelial expression of CD8+) and cell proliferation (p53 and p63) [62].…”

“…This study quantified the presence of these lymphocytes in conjunction with cell cycle regulators (p16, p53, p63, Ki-67 proteins) in 24 patients with histopathologically confirmed papillomas caused by human papillomavirus (HPV) infection, both before and after treatment with IL cidofovir [62]. The drug influence on the tissue was demonstrated via decreased inflammation (epithelial expression of CD8+) and cell proliferation (p53 and p63) [62]. Although no studies have quantified the drug influence of cidofovir on non-HPV induced tumors, cidofovir's suppression of cellular proliferation and inflammation may support its antineoplastic properties that have been suggested.…”